22 Results

People

  1. Giralt
    Giralt
  2. Korde
    Korde
  3. Usmani
    Usmani
  4. Hassoun
    Hassoun
  5. Landau
    Landau
  6. Landgren
    Landgren
  7. Lesokhin
    Lesokhin
  8. Shah
    Shah
  9. Chung
    Chung
  10. Hultcrantz
    Hultcrantz

Groups

  1. Department of Medicine (17)
  2. Hematologic Malignancies, Division of (16)
  3. Center for Hematologic Malignancies (15)
  4. Bone Marrow Transplant (8)
  5. Survivorship Research (7)
  6. Myeloma (6)
  7. CTCR Scholars (3)
  8. Hematologic Malignancies Research (3)
  9. Lymphoma (3)
  10. Hematology-Oncology Fellows (2)
  1. "ixazomib"
Formats
  1. Journal Article (12)
  2. Review (6)
  3. Conference Paper (1)
  4. Correspondence (1)
  5. Meeting Abstract (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (17)
  2. Hematologic Malignancies, Division of (16)
  3. Center for Hematologic Malignancies (15)
  4. Bone Marrow Transplant (8)
  5. Survivorship Research (7)
  6. Myeloma (6)

More Groups

People
  1. Sergio Giralt (5)
  2. Neha Korde (4)
  3. Saad Usmani (4)
  4. Alexander Lesokhin (3)
  5. Carl Landgren (3)
  6. Hani Hassoun (3)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (7)
  4. 2022 (2)
  5. 2021 (2)
  6. 2020 (3)

More Years

Publications
  1. American Journal of Hematology (3)
  2. Clinical Lymphoma, Myeloma and Leukemia (3)
  3. Blood Advances (2)
  4. Seminars in Hematology (2)
  5. The Lancet Haematology (2)
  6. Best Practice and Research: Clinical Haematology (1)

More Publications

Publishers
  1. Elsevier Inc. (8)
  2. John Wiley & Sons, Inc. (3)
  3. American Society of Hematology (2)
  4. Elsevier Science, Inc. (2)
  5. Nature Publishing Group (2)
  6. W.B. Saunders Co-Elsevier Inc. (2)

More Publishers

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Correspondence

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Burge, M.; Korde, N.; Hassoun, H.; Lesokhin, A.; Lahoud, O.; Smith, E.; Hultcrantz, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Current approaches to management of newly diagnosed multiple myeloma
    Review

    Goel, U.; Usmani, S.; Kumar, S.
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Kidney injury and disease in patients with haematological malignancies
    Review

    Bridoux, F.; Cockwell, P.; Glezerman, I.; Gutgarts, V.; Hogan, J. J.; Jhaveri, K. D.; Joly, F.; Nasr, S. H.; Sawinski, D.; Leung, N.
    Nature Reviews Nephrology (2021)

    Fulltext@MSK | Save
  • Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas
    Review

    Epstein-Peterson, Z. D.; Horwitz, S. M.
    Seminars in Hematology (2021)

    Fulltext@MSK | Save
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Journal Article

    Goldberg, A. D.; Atallah, E.; Rizzieri, D.; Walter, R. B.; Chung, K. Y.; Spira, A.; Stock, W.; Tallman, M. S.; Cruz, H. G.; Boni, J.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save
  • Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
    Review

    Diamond, B.; Maclachlan, K.; Chung, D. J.; Lesokhin, A. M.; Landgren, C. O.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis
    Meeting Abstract

    Sanchez, L.; Landau, H.; Rosenbaum, C.; Abrahams, A.; Chin, C.; Liotta, B.; Agudo, N.; Ramnath, S.; Hoover, E.; Rahman, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond
    Journal Article

    Chim, C. S.; Kumar, S. K.; Orlowski, R. Z.; Cook, G.; Richardson, P. G.; Gertz, M. A.; Giralt, S.; Mateos, M. V.; Leleu, X.; Anderson, K. C.
    Leukemia (2018)

    Fulltext@MSK | Save